Elidah develops non-invasive continence care centered on its Elitone neuromuscular therapy platform. The company addresses urinary incontinence in women and men with externally delivered treatments designed for convenient use at home. Its FDA-cleared product family includes solutions for stress and urge incontinence, as well as post-surgical needs, including recovery after prostate surgery. Elidah reports that its therapy has reached more than 40,000 users.

Elitone is designed to support pelvic floor function through targeted stimulation, offering a conservative option between exercises such as Kegels and interventions involving medication, surgery, or implants. The devices are built for comfort, fit, and ease of use, with a shared technology platform adapted to different populations and indications. In the United States, customers can order Elitone online without a prescription, with products shipped to their homes. Elidah also provides clinicians with educational materials and information to support use in clinical practice. Its commercial approach includes consumer access, clinician-directed care, telehealth integration, Medicare-covered indications, and strategic partnerships intended to expand access to its products.